TY - JOUR
T1 - Somatomedin-C in accelerated growth of children with precocious puberty
AU - Pescovitz, Ora Hirsch
AU - Rosenfeld, Ron G.
AU - Hintz, Raymond L.
AU - Barnes, Kevin
AU - Hench, Karen
AU - Comite, Florence
AU - Loriaux, D. Lynn
AU - Cutler, Gordon B.
PY - 1985/7
Y1 - 1985/7
N2 - To assess the role of somatomedin-C as a possible mediator of the growth spurt in children with central precocious puberty, we compared Sm-C levels in 40 children with central precocious puberty, 87 age-matched normal children, and 110 normal pubertal controls. Somatomedin C levels were significantly elevated for age in the children with precocious puberty (P<0.01), and were similar to the levels observed during normal puberty. The patients with precocious puberty were given the luteinizing hormone releasing hormone analogue d-Trp6-Pro9-NEt-LHRH (LHRHa) for 6 months. Treatment caused a significant decrease in secondary sexual characteristics, growth rate, plasma gonadotropins, sex steroids (estradiol in the girls and testosterone in the boys), and Sm-C levels. Growth during LHRHa treatment returned to the age-appropriate rate, whereas plasma Sm-C levels, although lower than pretreatment levels, remained significantly elevated for age (P<0.002). In addition, growth rates before and during treatment did not correlate with the plasma somatomedin C levels, nor did the decreases in growth rate during LHRHa therapy correlate with the decreases in somatomedin C levels. Growth rates did correlate significantly, however, with plasma estradiol levels in the girls (P<0.0005) and with plasma testosterone levels in the boys (P<0.025). We conclude that the growth spurt in children with precocious puberty cannot be explained by the plasma level of somatomedin C.
AB - To assess the role of somatomedin-C as a possible mediator of the growth spurt in children with central precocious puberty, we compared Sm-C levels in 40 children with central precocious puberty, 87 age-matched normal children, and 110 normal pubertal controls. Somatomedin C levels were significantly elevated for age in the children with precocious puberty (P<0.01), and were similar to the levels observed during normal puberty. The patients with precocious puberty were given the luteinizing hormone releasing hormone analogue d-Trp6-Pro9-NEt-LHRH (LHRHa) for 6 months. Treatment caused a significant decrease in secondary sexual characteristics, growth rate, plasma gonadotropins, sex steroids (estradiol in the girls and testosterone in the boys), and Sm-C levels. Growth during LHRHa treatment returned to the age-appropriate rate, whereas plasma Sm-C levels, although lower than pretreatment levels, remained significantly elevated for age (P<0.002). In addition, growth rates before and during treatment did not correlate with the plasma somatomedin C levels, nor did the decreases in growth rate during LHRHa therapy correlate with the decreases in somatomedin C levels. Growth rates did correlate significantly, however, with plasma estradiol levels in the girls (P<0.0005) and with plasma testosterone levels in the boys (P<0.025). We conclude that the growth spurt in children with precocious puberty cannot be explained by the plasma level of somatomedin C.
UR - http://www.scopus.com/inward/record.url?scp=0021864634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021864634&partnerID=8YFLogxK
U2 - 10.1016/S0022-3476(85)80607-7
DO - 10.1016/S0022-3476(85)80607-7
M3 - Article
C2 - 3891947
AN - SCOPUS:0021864634
VL - 107
SP - 20
EP - 25
JO - Journal of Pediatrics
JF - Journal of Pediatrics
SN - 0022-3476
IS - 1
ER -